Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Beta… Read more
Eton Pharmaceuticals Inc (ETON) - Total Assets
Latest total assets as of September 2025: $104.51 Million USD
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) holds total assets worth $104.51 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eton Pharmaceuticals Inc - Total Assets Trend (2017–2024)
This chart illustrates how Eton Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eton Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Eton Pharmaceuticals Inc's total assets of $104.51 Million consist of 53.9% current assets and 46.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $5.36 Million | 7.0% |
| Inventory | $15.23 Million | 20.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $34.88 Million | 45.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Eton Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eton Pharmaceuticals Inc's current assets represent 53.9% of total assets in 2024, a decrease from 98.9% in 2017.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2024, down from 97.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 45.8% of total assets.
Eton Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eton Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Eton Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Eton Pharmaceuticals Inc generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Eton Pharmaceuticals Inc is currently not profitable relative to its asset base.
Eton Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.51 | 6.51 |
| Quick Ratio | 1.25 | 1.41 | 6.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.82 Million | $ 10.02 Million | $ 20.91 Million |
Eton Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eton Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.49 |
| Latest Market Cap to Assets Ratio | 4.43 |
| Asset Growth Rate (YoY) | 139.8% |
| Total Assets | $76.12 Million |
| Market Capitalization | $337.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eton Pharmaceuticals Inc's assets at a significant premium ( 4.43x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eton Pharmaceuticals Inc's assets grew by 139.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eton Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of Eton Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $76.12 Million | +139.83% |
| 2023-12-31 | $31.74 Million | +26.81% |
| 2022-12-31 | $25.03 Million | -8.87% |
| 2021-12-31 | $27.46 Million | +4.35% |
| 2020-12-31 | $26.32 Million | +54.16% |
| 2019-12-31 | $17.07 Million | -39.73% |
| 2018-12-31 | $28.33 Million | +110.72% |
| 2017-12-31 | $13.44 Million | -- |